spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bromfenac 

 HSMN NewsFeed - 3 Jan 2018
Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa(R) Ophthalmic Solution 0.07%
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 27 Aug 2015
InSite Vision and QLT Amend Merger Agreement
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 18 Dec 2013
InSite Vision Announces Positive Confirmatory Phase 3 Results for BromSite(TM) for the Reduction of Inflammation and Pain after Cataract Surgery
Biopharmaceuticals Drug Delivery Ophthalmology Surgery
 HSMN NewsFeed - 13 Oct 2011
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Nov 2010
ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Sep 2009
Bausch & Lomb Subsidiaries and CROMA will Co-Promote Bromfenac Ophthalmic Solution in Europe
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Nov 2007
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Feb 2007
ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 May 2006
ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 May 2006
ISTA Pharmaceuticals(R) Announces Study Indicating Twice-Daily Dosing of Xibrom(TM) as Equivalent to Four Times a Day of Other Treatments
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
bromfenac
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.